Search
Research
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trialAs part of the accelerated development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we report a dose-finding and adjuvant justification study of SCB-2019, a protein subunit vaccine candidate containing a stabilised trimeric form of the spike (S)-protein (S-Trimer) combined with two different adjuvants.
Research
An observational study of the reactogenicity and immunogenicity of 13-valent pneumococcal conjugate vaccine in women of childbearing age in Papua New GuineaMaternal immunization with pneumococcal conjugate vaccine (PCV) may protect young infants in high-risk settings against the high risk of pneumococcal infections in early life. The aim of this study was to determine the safety and immunogenicity of 13-valent PCV (PCV13) in healthy women of childbearing age in PNG.
Research
AMEND study protocol: A case-control study to assess the long-term impact of invasive meningococcal disease in Australian adolescents and young adultsThis study aims to address this evidence gap by assessing the clinical, physical, neurocognitive, economic and societal impact of invasive meningococcal disease
Research
ATOMIC Ears: A Phase IIB randomised controlled trial to assess safety, tolerability and acceptability of a 5-day Dornase alfa treatment as an adjunct therapy to ventilation tube insertion for otitis media in childrenChris Jennifer Lea-Ann Peter Ruth Brennan-Jones Kent Kirkham Richmond Thornton PhD RN PhD MBBS MRCP(UK) FRACP PhD Head, Ear and Hearing Health
Research
COVALIA (COVid vaccine trial for austrALIA): A phase I, double-blind, dose-ranging, randomised, placebo-controlled trial to study the safety and immunogenicity of a DNA-based vaccine against COVID-19 (COVIGEN) in healthy participants aged 18 to 75 years oPeter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group
Research
Neutrophil Extracellular Traps and Bacterial Biofilms in Middle Ear Effusion of Children with Recurrent Acute Otitis MediaBacteria persist within biofilms on the middle ear mucosa of children with recurrent and chronic otitis media however the mechanisms by which these...
Research
Neonatal antigen-presenting cells are functionally more quiescent in children born under traditional compared with modern environmental conditionsOne explanation for the high burden of allergic and autoimmune diseases in industrialized countries is inappropriate immune development under modern...
Research
Children with otitis media mount a pneumococcal serotype specific serum IgG and IgA response comparable to healthy controls after pneumococcal conjugate vaccinationWe investigated the suggestion that otitis-prone children have an impaired antibody response in the context of pneumococcal vaccination.
Research
Molecular surveillance of true nontypeable haemophilus influenzae: An evaluation of pcr screening assaysUnambiguous identification of nontypeable Haemophilus influenzae (NTHi) is not possible by conventional microbiology. Molecular characterisation of...
Research
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasiaWe report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PApilloma TRIal against Cancer In young Adults.